Electroneutral polymersomes for combined cancer chemotherapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Combination cancer chemotherapy is crucial for treating various cancers.
• Drug delivery systems (DDS) are increasingly important for enhancing combination therapy efficacy and managing side effects.
• Polymersomes offer advantages over liposomes for DDS due to higher drug loading capacity and stability.

Purpose of the Study:

• To formulate and evaluate a novel electroneutral polymersome for co-delivering Doxorubicin, 5-Fluorouracil, and leucovorin.
• To assess the in vitro and in vivo efficacy, biodistribution, and toxicity of the combination drug-loaded polymersomes.
• To compare the performance of the polymersomal DDS with free drug solutions in preclinical cancer models.

Main Methods:

• Formulation of a novel electroneutral polymersome for high encapsulation of multiple chemotherapeutic drugs.
• In vitro evaluation using the BxPC-3 cell line.
• In vivo studies involving intratumoral and intravenous administration in tumor-bearing models.
• Biodistribution studies to determine drug accumulation in tumor tissue.
• Assessment of maximum tolerated dose and gene expression analysis.

Main Results:

• The novel polymersome achieved high encapsulation efficiencies for Doxorubicin, 5-Fluorouracil, and leucovorin.
• Polymersomes demonstrated significant accumulation in tumor tissue.
• In vitro and in vivo studies showed superior efficacy and higher maximum tolerated dose for the combination drug-loaded polymersomes compared to free drugs.
• Intratumoral administration resulted in a 62% reduction in tumor volume, while intravenous administration showed a 13% reduction with reduced cardiotoxicity.
• Gene expression analysis indicated significant differences between polymersome-treated and free drug-treated tumors.

Conclusions:

• The developed electroneutral polymersome is a promising DDS for combination cancer chemotherapy.
• This DDS enhances therapeutic efficacy, reduces systemic toxicity, and overcomes drug resistance.
• The findings support the potential of polymersomes in advancing combination cancer therapy and improving patient outcomes.